Furthermore PPARγ is thought to be one of the molecular targets underlying the beneficial anti-inflammatory effect of 5-aminosalicylic acid, a drug widely used to treat inflammatory bowel diseases (IBDs) [109]. The gene discussed is PPARG; the disease is inflammatory bowel disease.